Synairgen plc (LON:SNG)‘s stock had its “corporate” rating reissued by stock analysts at FinnCap in a note issued to investors on Wednesday. They presently have a GBX 137 ($1.70) price objective on the stock.

Separately, N+1 Singer lowered their target price on shares of Synairgen plc from GBX 47 ($0.58) to GBX 46 ($0.57) and set a “buy” rating on the stock in a report on Thursday, September 22nd.

Shares of Synairgen plc (LON:SNG) opened at 21.25 on Wednesday. Synairgen plc has a 12-month low of GBX 19.00 and a 12-month high of GBX 38.00. The stock’s 50 day moving average is GBX 33.01 and its 200-day moving average is GBX 31.17. The firm’s market cap is GBX 19.41 million.

Synairgen plc Company Profile

Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls).

Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with's FREE daily email newsletter.